Screener
Alamar Biosciences ALMR Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 13,017 | 8,302 |
| Selling, general and administrative | 13,787 | 6,640 |
| Total operating expenses | 26,804 | 14,942 |
| Loss from operations | (12,347) | (8,553) |
| Interest income, net | 539 | 786 |
| Interest expense | (223) | (46) |
| Loss on remeasurement of convertible notes | (8,594) | — |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's total operating expenses?
- Alamar Biosciences (ALMR) reported total operating expenses of $26.8M in Q1 2026.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Alamar Biosciences's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude